Explore

Trendline Trendline
Supernus Pharmaceuticals Reports Q1 CY2026 Sales Surpassing Expectations Despite Earnings Miss

Supernus Pharmaceuticals Reports Q1 CY2026 Sales Surpassing Expectations Despite Earnings Miss

Supernus Pharmaceuticals Reports Q1 CY2026 Sales Surpassing Expectations Despite Earnings Miss
Trendline Trendline
IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance

IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance

IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Trendline Trendline
IQVIA Reports Strong Q1 2026 Results with Revenue and Earnings Growth

IQVIA Reports Strong Q1 2026 Results with Revenue and Earnings Growth

IQVIA Reports Strong Q1 2026 Results with Revenue and Earnings Growth
Trendline Trendline
Coeur Mining Reports Q1 Earnings Below Expectations Amid Revenue Growth

Coeur Mining Reports Q1 Earnings Below Expectations Amid Revenue Growth

Coeur Mining Reports Q1 Earnings Below Expectations Amid Revenue Growth
Trendline Trendline
Baxter's Q1 Earnings Call Highlights Turnaround Strategy Amid Challenges

Baxter's Q1 Earnings Call Highlights Turnaround Strategy Amid Challenges

Baxter's Q1 Earnings Call Highlights Turnaround Strategy Amid Challenges
Trendline Trendline
Coeur Mining Reports Q1 Earnings Below Expectations, Revenue Surpasses Estimates

Coeur Mining Reports Q1 Earnings Below Expectations, Revenue Surpasses Estimates

Coeur Mining Reports Q1 Earnings Below Expectations, Revenue Surpasses Estimates
Trendline Trendline
GoodRx Reports Decrease in Revenue but Raises Full Year 2026 Expectations

GoodRx Reports Decrease in Revenue but Raises Full Year 2026 Expectations

GoodRx Reports Decrease in Revenue but Raises Full Year 2026 Expectations
Trendline Trendline
Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches

Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches

Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches
Trendline Trendline
Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings
Trendline Trendline
Palantir Technologies Reports Significant Q1 2026 Revenue Growth, Raises Full-Year Guidance

Palantir Technologies Reports Significant Q1 2026 Revenue Growth, Raises Full-Year Guidance

Palantir Technologies Reports Significant Q1 2026 Revenue Growth, Raises Full-Year Guidance